Ecnoglutide: Dosing Protocols

Investigational Status#

Ecnoglutide (XW003) is an investigational drug currently in Phase 3 clinical trials. It is not approved by any regulatory authority and is not available outside of clinical trials. All dosing information presented here is derived from published clinical trial protocols and results. This information is provided for educational and research reference purposes only.

Clinical Trial Dosing#

SLIMMER Phase 3 Trial (Obesity)#

The SLIMMER trial was the pivotal Phase 3 obesity study, enrolling 664 Chinese adults with overweight or obesity. Participants were randomized to three dose levels of ecnoglutide or placebo for 48 weeks:

The trial used dose escalation from lower starting doses, though the specific escalation schedule has not been publicly detailed. The treatment duration was 40 weeks of active dosing with assessment extending to 48 weeks.

Phase 2 Type 2 Diabetes Trial#

The Phase 2 trial enrolled 145 adults with type 2 diabetes, randomized to ecnoglutide 0.4 mg, 0.8 mg, or 1.2 mg, or placebo as once-weekly injections for 20 weeks.

All active treatment arms achieved statistically significant HbA1c reductions compared to placebo (P < 0.0001).

Phase 3 EECOH-1 Trial (Type 2 Diabetes)#

The Phase 3 EECOH-1 trial enrolled 211 participants at 33 sites in China, evaluating ecnoglutide 0.6 mg and 1.2 mg versus placebo as once-weekly injections for 24 weeks. Results showed HbA1c reductions comparable to those seen with dual GLP-1/GIP agonists.

Administration#

Route and Frequency#

Ecnoglutide is administered as a once-weekly subcutaneous injection. The half-life of 124-138 hours at steady state supports this dosing frequency. Injections are typically administered on the same day each week.

Dose Escalation#

Clinical trials employed dose escalation protocols to improve gastrointestinal tolerability, consistent with standard practice for GLP-1 receptor agonists. Specific escalation schedules from starting dose to maintenance dose have not been fully disclosed in publicly available data.

Oral Formulation (XW004)#

Sciwind Biosciences is also developing XW004, an oral formulation of ecnoglutide. A Phase 1 trial of XW004 showed positive results, though detailed dosing and efficacy data have not been fully disclosed. This oral formulation could expand access to ecnoglutide therapy, analogous to the relationship between injectable semaglutide (Ozempic/Wegovy) and oral semaglutide (Rybelsus).

Dosing Context#

Ecnoglutide belongs to the Metabolic category of research peptides. Dosing protocols for Ecnoglutide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for Ecnoglutide:

Weight Management (SLIMMER Phase 3 Trial)#

Dose: Dose escalation from starting dose to maintenance doses of 1.2 mg, 1.8 mg, or 2.4 mg once weekly subcutaneous injection over 40-48 weeks.

Frequency: Once weekly subcutaneous injection

Duration: 48 weeks (clinical trial duration)

The SLIMMER Phase 3 trial enrolled 664 participants randomized to ecnoglutide 1.2 mg, 1.8 mg, or 2.4 mg or placebo. Mean weight loss was 15.4% at 48 weeks with the highest dose. 92.8% achieved at least 5% weight loss.

Type 2 Diabetes (Phase 2 Trial)#

Dose: 0.4 mg, 0.8 mg, or 1.2 mg once weekly subcutaneous injection for 20 weeks.

Frequency: Once weekly subcutaneous injection

Duration: 20 weeks (Phase 2 trial duration)

HbA1c reductions of -1.81% (0.4 mg), -1.90% (0.8 mg), and -2.39% (1.2 mg) versus -0.55% for placebo at 20 weeks.

Type 2 Diabetes (Phase 3 EECOH Trial)#

Dose: 0.6 mg or 1.2 mg once weekly subcutaneous injection for 24 weeks.

Frequency: Once weekly subcutaneous injection

Duration: 24 weeks (Phase 3 trial duration)

Phase 3 trial at 33 sites in China with 211 participants. HbA1c reductions were comparable to dual GLP-1/GIP analogs such as tirzepatide.

Reconstitution and Preparation#

Ecnoglutide is an investigational compound currently available only in clinical trials. Formulation details have not been publicly disclosed. In clinical trials, it was administered as a subcutaneous injection, likely as a pre-formulated solution.

Injection Sites#

Recommended injection sites for Ecnoglutide include:

• Abdomen
• Thigh

Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.

Storage Requirements#

Storage conditions for ecnoglutide have not been publicly disclosed. As a peptide-based injectable, it is expected to require refrigerated storage at 2-8 degrees C, consistent with other GLP-1 receptor agonists.

Related Reading#

• Ecnoglutide overview and research guide
• Ecnoglutide side effects profile
• Ecnoglutide research evidence